CRISPR Therapeutics' SWOT analysis: gene editing pioneer's stock faces pivotal year
CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...
Vertex Pharmaceuticals (VRTX) Dips More Than Broader Market: What You Should Know
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $416.96, moving -1.72% from the previous trading session.
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors
Vertex Pharmaceuticals Inc. closed 19.80% below its 52-week high of $519.88, which the company reached on November 8th.
HHS Challenges Vertex Over Fertility Services Program Tied To Casgevy Gene Therapy, Says Company Is 'Grasping at Straws'
HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...
BioPharma Dive20h
Roche’s new deals head tries to navigate a more ‘complicated’ and ‘expensive’ biotech world
Roche's core research spans five large areas. Boris Zaïtra, who now leads corporate business development, is confident his ...
Promising Developments and Strategic Partnerships Drive Crispr Therapeutics’ Growth Potential
William Blair analyst Sami Corwin has maintained their bullish stance on CRSP stock, giving a Buy rating on January 14.Stay Ahead of the ...
2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows
With that in mind, let's consider two stocks that haven't performed well recently and are now near their 52-week lows but that are still worth investing in: CRISPR Therapeutics (NASDAQ: CRSP) and ...